<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Yang Y</submitter><pubmed_abstract>The persistent emergence of SARS-CoV-2 variants continues to compromise current vaccine efficacy, driving the development of broad-spectrum coronavirus vaccines to address variant evasion and future outbreaks. To develop a pan-coronavirus vaccine, we identified some conserved T/B epitopes across spike proteins of human-infecting coronaviruses, focusing on two conserved long peptides, VV and VS, which demonstrated broad immunogenicity in PBMCs from COVID-19 convalescent patients. By structurally fusing the VV and VS long peptides with heptad repeat 1/2 (HR1/2) domains from the S2 subunit, we engineered a trimeric immunogen HR1-VV-HR2-VS. This design induced superior cellular and humoral immune responses compared to individual peptide components in immunized mice. The vaccine also significan</pubmed_abstract><journal>Emerging microbes &amp; infections</journal><pagination>2631206</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12927409</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.</pubmed_title><pmcid>PMC12927409</pmcid><pubmed_authors>Hong M</pubmed_authors><pubmed_authors>Yao J</pubmed_authors><pubmed_authors>Lu X</pubmed_authors><pubmed_authors>Ding C</pubmed_authors><pubmed_authors>Li E</pubmed_authors><pubmed_authors>Xing Y</pubmed_authors><pubmed_authors>He H</pubmed_authors><pubmed_authors>Jin T</pubmed_authors><pubmed_authors>Feng F</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Ye X</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Tan W</pubmed_authors><pubmed_authors>Cheng Q</pubmed_authors><pubmed_authors>Huang X</pubmed_authors><pubmed_authors>Zhao G</pubmed_authors><pubmed_authors>Shang Y</pubmed_authors><pubmed_authors>Chen Y</pubmed_authors><pubmed_authors>Zou R</pubmed_authors><pubmed_authors>Li B</pubmed_authors><pubmed_authors>Chiu S</pubmed_authors><pubmed_authors>Huang B</pubmed_authors><pubmed_authors>Tang Y</pubmed_authors><pubmed_authors>Tong D</pubmed_authors></additional><is_claimable>false</is_claimable><name>Receptor binding domain-independent pancoronavirus vaccine design by fusion of conserved T/B Epitopes.</name><description>The persistent emergence of SARS-CoV-2 variants continues to compromise current vaccine efficacy, driving the development of broad-spectrum coronavirus vaccines to address variant evasion and future outbreaks. To develop a pan-coronavirus vaccine, we identified some conserved T/B epitopes across spike proteins of human-infecting coronaviruses, focusing on two conserved long peptides, VV and VS, which demonstrated broad immunogenicity in PBMCs from COVID-19 convalescent patients. By structurally fusing the VV and VS long peptides with heptad repeat 1/2 (HR1/2) domains from the S2 subunit, we engineered a trimeric immunogen HR1-VV-HR2-VS. This design induced superior cellular and humoral immune responses compared to individual peptide components in immunized mice. The vaccine also significan</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Dec</publication><modification>2026-07-16T18:30:44.043Z</modification><creation>2026-07-11T03:08:37.337Z</creation></dates><accession>S-EPMC12927409</accession><cross_references><pubmed>41672103</pubmed><doi>10.1080/22221751.2026.2631206</doi></cross_references></HashMap>